Jonas F Ludvigsson1,2,3, Martin Neovius4, Lennart Hammarström5. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. jonasludvigsson@yahoo.com. 2. Department of Paediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden. jonasludvigsson@yahoo.com. 3. Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK. jonasludvigsson@yahoo.com. 4. Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. 5. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Abstract
PURPOSE: To explore the risk of infections in individuals with IgA deficiency compared to general population controls. METHODS: In this nationwide prospective population-based cohort study, we used data on IgA levels (<0.07 g/L) from six university hospitals in Sweden to identify 2100 individuals with IgA deficiency. Individuals were diagnosed between 1980 and 2010. For each patient with IgA deficiency we identified 10 controls from the general population, matched on age, sex, and place of residence (n = 18,653). Data on infections were obtained from the Swedish National Patient Register (including inpatient and hospital-based outpatient care) between 2001 and 2010. We defined infections as having a record of a relevant international classification of disease (ICD) code. Prevalences and prevalence ratios (PRs) were calculated. RESULTS: Individuals with IgA deficiency were more likely to have a record of any infection (36.1 vs. 18.8% in controls) corresponding to a PR of 2.4 (95%CI 2.2-2.6). We also noted statistically significant associations with IgA deficiency (all P-values <0.05) and respiratory tract infections (17.8 vs. 6.3% in controls; PR = 3.2), gastrointestinal infections (6.0 vs. 1.8% in controls; PR = 3.5), skin infections (4.1 vs. 2.2% in controls; PR = 1.9), joint infections (0.48 vs. 0.24% in controls; PR = 2.0; P = 0.052), sepsis (1.5 vs. 0.45% in controls; PR = 3.4), meningitis (0.38 vs. 0.12%, PR = 3.2), mastoiditis/otitis (2.1 vs. 1.1% in controls; PR = 2.0), and urinary tract infections (6.1 vs. 3.4% in controls; PR = 1.8). CONCLUSIONS: Individuals with IgA deficiency are at an increased risk of infections requiring hospital care.
PURPOSE: To explore the risk of infections in individuals with IgA deficiency compared to general population controls. METHODS: In this nationwide prospective population-based cohort study, we used data on IgA levels (<0.07 g/L) from six university hospitals in Sweden to identify 2100 individuals with IgA deficiency. Individuals were diagnosed between 1980 and 2010. For each patient with IgA deficiency we identified 10 controls from the general population, matched on age, sex, and place of residence (n = 18,653). Data on infections were obtained from the Swedish National Patient Register (including inpatient and hospital-based outpatient care) between 2001 and 2010. We defined infections as having a record of a relevant international classification of disease (ICD) code. Prevalences and prevalence ratios (PRs) were calculated. RESULTS: Individuals with IgA deficiency were more likely to have a record of any infection (36.1 vs. 18.8% in controls) corresponding to a PR of 2.4 (95%CI 2.2-2.6). We also noted statistically significant associations with IgA deficiency (all P-values <0.05) and respiratory tract infections (17.8 vs. 6.3% in controls; PR = 3.2), gastrointestinal infections (6.0 vs. 1.8% in controls; PR = 3.5), skin infections (4.1 vs. 2.2% in controls; PR = 1.9), joint infections (0.48 vs. 0.24% in controls; PR = 2.0; P = 0.052), sepsis (1.5 vs. 0.45% in controls; PR = 3.4), meningitis (0.38 vs. 0.12%, PR = 3.2), mastoiditis/otitis (2.1 vs. 1.1% in controls; PR = 2.0), and urinary tract infections (6.1 vs. 3.4% in controls; PR = 1.8). CONCLUSIONS: Individuals with IgA deficiency are at an increased risk of infections requiring hospital care.
Entities:
Keywords:
IgA deficiency; Immunoglobulin; Infections
Authors: G H Jorgensen; A Gardulf; M I Sigurdsson; S Th Sigurdardottir; I Thorsteinsdottir; S Gudmundsson; L Hammarström; B R Ludviksson Journal: J Clin Immunol Date: 2013-02-07 Impact factor: 8.317
Authors: Luigi D Notarangelo; Alain Fischer; Raif S Geha; Jean-Laurent Casanova; Helen Chapel; Mary Ellen Conley; Charlotte Cunningham-Rundles; Amos Etzioni; Lennart Hammartröm; Shigeaki Nonoyama; Hans D Ochs; Jennifer Puck; Chaim Roifman; Reinhard Seger; Josiah Wedgwood Journal: J Allergy Clin Immunol Date: 2009-12 Impact factor: 10.793
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Yoichi Furuya; Girish S Kirimanjeswara; Sean Roberts; Rachael Racine; Jennifer Wilson-Welder; Alan M Sanfilippo; Sharon L Salmon; Dennis W Metzger Journal: Vaccine Date: 2017-07-31 Impact factor: 3.641
Authors: Louise Emilsson; Benjamin Lebwohl; Peter Hr Green; Joseph A Murray; Karl Mårild; Jonas F Ludvigsson Journal: United European Gastroenterol J Date: 2017-04-24 Impact factor: 4.623
Authors: Antony R Parker; Markus Skold; David B Ramsden; J Gonzalo Ocejo-Vinyals; Marcos López-Hoyos; Stephen Harding Journal: Lab Med Date: 2017-11-08